|Bid||26.57 x 3200|
|Ask||26.71 x 1400|
|Day's Range||26.32 - 33.46|
|52 Week Range||17.00 - 40.82|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||42.00|
Nuvalent, Inc., (Nasdaq: NUVL), a biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today reported recent pipeline and business highlights and second quarter 2021 financial results.
Baupost Group disclosed a large stake in biotech Translate Bio. Bain Capital Life Sciences initiated a big investment in biopharmaceutical firm Nuvalent.
Nuvalent, Inc., a biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the closing of its upsized initial public offering of 11,212,500 shares of common stock, consisting of 10,612,500 shares of Class A common stock and 600,000 shares of Class B common stock, which includes 1,462,500 shares of Class A common stock sold pursuant to the exercise in full by the underwriters of their option to purchase additional s